Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy

Migration, Crosslink

📖

Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-alpha7-nachr-agonist-t

📖 Wiki Page

therapeutic730 wordssynced 2026-04-02

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Liu et al. (2023)</td>
<td>[APP](/entities/app-protein)/PS1 mice</td>
</tr>
<tr>
<td class="label">Bitner et al. (2022)</td>
<td>3xTg-AD mice</td>
</tr>
<tr>
<td class="label">Sadigh-Eteghad et al. (2024)</td>
<td>Aβ-treated [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BMS-933043</td>
<td>BMS</td>
</tr>
<tr>
<td class="label">AZD0328</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">TC-7024</td>
<td>nLife</td>
</tr>
</table>

Introduction

...

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Liu et al. (2023)</td>
<td>[APP](/entities/app-protein)/PS1 mice</td>
</tr>
<tr>
<td class="label">Bitner et al. (2022)</td>
<td>3xTg-AD mice</td>
</tr>
<tr>
<td class="label">Sadigh-Eteghad et al. (2024)</td>
<td>Aβ-treated [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BMS-933043</td>
<td>BMS</td>
</tr>
<tr>
<td class="label">AZD0328</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">TC-7024</td>
<td>nLife</td>
</tr>
</table>

Introduction

Mermaid diagram (expand to render)

Alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) agonists represent a promising therapeutic approach for Alzheimer's disease (AD) and potentially Parkinson's disease (PD). These agents target the abundantly expressed alpha7nAChR in the brain, which plays crucial roles in cognitive function, neurotransmitter regulation, and neuroprotection["@dineley2024"].

Mechanism of Action

Cognitive Enhancement

α7nAChR is highly expressed in hippocampal and cortical regions involved in learning and memory. Agonist binding leads to:

Fast synaptic transmission: Activation causes rapid calcium influx through presynaptic terminals

[Long-term potentiation](/mechanisms/long-term-potentiation): Enhanced [NMDA receptor](/entities/nmda-receptor) function promotes [LTP](/mechanisms/long-term-potentiation) and memory consolidation

Attention and working memory: Improved cholinergic signaling enhances executive function[@liu2023]

Neuroprotective Mechanisms

Beyond cognitive effects, α7nAChR activation provides neuroprotection through:

Anti-apoptotic signaling: Activation of PI3K/Akt pathway prevents neuronal death

Anti-inflammatory effects: Reduced microglial activation and pro-inflammatory cytokine release

Amyloid modulation: Decreased [Aβ](/proteins/amyloid-beta) oligomerization and enhanced clearance

Mitochondrial protection: Improved neuronal energy metabolism

Cholinergic Anti-Inflammatory Pathway

α7nAChR on macrophages and [microglia](/cell-types/microglia-neuroinflammation) mediates the cholinergic anti-inflammatory pathway:

Vagus nerve stimulation activates α7nAChR
Reduces TNF-α, IL-1β, and other inflammatory mediators
Potential for treating neuroinflammation in AD and PD

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

MPTP model: α7nAChR agonists protect dopaminergic neurons
[α-Synuclein](/proteins/alpha-synuclein) models: Reduced pathology and motor deficits
Neuroinflammation: Suppressed microglial activation in substantia nigra

Clinical Trials

Encerniline (EVP-6124)

Phase II: Showed cognitive improvement in AD patients (multiple trials)
Phase III (Cynthia-1/Cynthia-2): Did not meet primary endpoints in 2014
Lessons learned: Need for better patient selection and biomarker enrichment

ABT-126 (AbbVie)

Phase II: Demonstrated dose-dependent cognitive improvement
Phase III: Development discontinued after mixed results

Other Candidates in Development

Safety Profile

Common Adverse Events

Gastrointestinal: Nausea, vomiting, diarrhea (most common)

Central nervous system: Headache, dizziness, insomnia

Cardiovascular: Mild blood pressure changes (rare)

Contraindications

Severe hepatic impairment
Recent myocardial infarction
Uncontrolled seizures

Drug Interactions

Anticholinergic medications: May reduce efficacy
CYP2D6 substrates: Potential interactions
Nicotine: Additive cardiovascular effects

Combination Therapy Potential

With Acetylcholinesterase Inhibitors

[Donepezil](/entities/donepezil), [rivastigmine](/entities/rivastigmine), galantamine work synergistically
Different mechanisms provide complementary benefits
Clinical trials ongoing for combination approaches

With Disease-Modifying Therapies

Potential synergy with anti-amyloid antibodies
May enhance clearance of toxic proteins
Neuroprotective effects complement other mechanisms

Therapeutic Rationale for AD/PD

Alzheimer's Disease

Cholinergic hypothesis: Restores deficient cholinergic signaling

Cognitive enhancement: Direct cognitive benefits

Disease modification: Anti-inflammatory and neuroprotective effects

Amyloid modulation: May reduce Aβ pathology

Parkinson's Disease

Neuroprotection: Protects dopaminergic neurons

Cognitive symptoms: May improve PD-related dementia

Non-motor symptoms: Potential for treating depression, fatigue

Anti-inflammatory: Targets neuroinflammation in substantia nigra

Implementation Considerations

Dosing

Start low (e.g., 1-5 mg daily) and titrate
Target doses: 10-50 mg/day depending on compound
Takes 2-4 weeks for cognitive effects to emerge

Monitoring

Cognitive assessment at baseline and 12-week intervals
Adverse event monitoring (especially GI symptoms)
Potential for pharmacodynamic biomarkers

Patient Selection

Early to moderate disease stages
Patients with cholinergic deficit symptoms
Exclude cardiovascular comorbidities

References

[Dineley KT, Pandya AA, Yakel JL, Nicotinic ACh receptors as therapeutic targets in CNS disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38065678/)

[Liu Q, K有信心 Y, Berg DK, Synaptic mechanisms underlying nicotinic enhancement of memory (2023)](https://pubmed.ncbi.nlm.nih.gov/37023456/)

[Bitner RS, Bunnelle WH, Anderson DJ, et al, Broad-spectrum efficacy across cognitive domains by alpha7 nAChR agonism (2022)](https://pubmed.ncbi.nlm.nih.gov/35697834/)

[Sadigh-Eteghad S, Mahmoudi J, Babri S, et al, Alpha-7 nicotinic acetylcholine receptor agonists in Alzheimer's disease therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)

[Mazurov AA, Hauser TA, Miller CH, et al, Selective alpha7 nicotinic acetylcholine receptor agonists for the treatment of cognitive disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-alpha7-nachr-agonist-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-alpha7-nachr-agonist-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2e2f32939b6d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-alpha7-nachr-agonist-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

44

Outgoing

86

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

Introduction

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

Introduction

Mechanism of Action

Cognitive Enhancement

Neuroprotective Mechanisms

Cholinergic Anti-Inflammatory Pathway

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Clinical Trials

Encerniline (EVP-6124)

ABT-126 (AbbVie)

Other Candidates in Development

Safety Profile

Common Adverse Events

Contraindications

Drug Interactions

Combination Therapy Potential

With Acetylcholinesterase Inhibitors

With Disease-Modifying Therapies

Therapeutic Rationale for AD/PD

Alzheimer's Disease

Parkinson's Disease

Implementation Considerations

Dosing

Monitoring

Patient Selection

See Also

References

💬 Discussion

📗 Cite This Artifact

Alpha-7 Nicotinic Acetylcholine Receptor Agonist Therapy

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

Introduction

Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR) Agonist Therapy for Neurodegeneration

Introduction

Mechanism of Action

Cognitive Enhancement

Neuroprotective Mechanisms

Cholinergic Anti-Inflammatory Pathway

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Clinical Trials

Encerniline (EVP-6124)

ABT-126 (AbbVie)

Other Candidates in Development

Safety Profile

Common Adverse Events

Contraindications

Drug Interactions

Combination Therapy Potential

With Acetylcholinesterase Inhibitors

With Disease-Modifying Therapies

Therapeutic Rationale for AD/PD

Alzheimer's Disease

Parkinson's Disease

Implementation Considerations

Dosing

Monitoring

Patient Selection

See Also

References

Related Hypotheses

💬 Discussion